Menu Search
Equities

Krishna Institute of Medical Sciences Ltd

KIMS:NSI

Krishna Institute of Medical Sciences Ltd

Actions
Health CareHealth Care Providers
  • Price (INR)595.25
  • Today's Change11.50 / 1.97%
  • Shares traded1.50m
  • 1 Year change+53.41%
  • Beta0.3950
Data delayed at least 15 minutes, as of Nov 22 2024 10:27 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 19-Nov-24
Select bar for recommendation details.
Recommendations19-Nov-24
Buy4
Outperform4
Hold1
Sell0
Strong Sell0

Share price forecast in INR

The 9 analysts offering 12 month price targets for Krishna Institute Of Medical Sciencs Ltd have a median target of 625.00, with a high estimate of 675.00 and a low estimate of 406.40. The median estimate represents a 7.07% increase from the last price of 583.75.
High15.6%675.00
Med7.1%625.00
Low-30.4%406.40

Earnings history & estimates in INR

On Nov 09, 2024, Krishna Institute Of Medical Sciencs Ltd reported 2nd quarter 2025 earnings of 2.68 per share. This result was in line with the expectation of the one analyst following the company and exceeded last year's 2nd quarter results by 16.52%.
The next earnings announcement is expected on May 20, 2025.
Average growth rate+6.32%
Krishna Institute Of Medical Sciencs Ltd reported annual 2024 earnings of 7.75 per share on May 16, 2024.
Average growth rate-3.56%
More ▼

Revenue history & estimates in INR

Krishna Institute Of Medical Sciencs Ltd had 2nd quarter 2025 revenues of 7.77bn. This bettered the 7.52bn consensus of the 5 analysts covering the company. This was 19.13% above the prior year's 2nd quarter results.
Average growth rate+4.75%
Krishna Institute Of Medical Sciencs Ltd had revenues for the full year 2024 of 24.98bn. This was 13.67% above the prior year's results.
Average growth rate+13.67%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.